NeuroModulation Technique Treatment of Autism

Inclusion Criteria:

• Qualified participants are those who have received a formal diagnosis of autism from aphysician or psychologist using DSM-IV, DSM-IV-TR or ICD-9-CM diagnostic criteria.Parents and/or legal guardian must supply proof of autism diagnosis. Autism (DSM-IV,DSM-IV-R or ICD-9-CM 299.0) must be diagnosed - any other diagnosis such as PervasiveDevelopmental Disorder (PDD), Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) or Asperger Syndrome is not sufficient for inclusion in this study.

• Children must have had their diagnosis of autism for at least one year prior to thedate of the application for participation in this study.

• Children must not have started any new therapies or stopped any ongoing therapiesdesigned to treat their autism such behavior therapy, speech therapy, physicaltherapy, sensory integration, dietary modification or dietary supplementation, or anyalternative or experimental therapies not mentioned here in the 6 months prior to thedate of the application for participation in this study.

• During the course of this study, children will be required to continue with anytherapies they have been receiving prior to starting the study, and they will berequired to not start any new therapies besides NeuroModulation Technique during thecourse of this study.

• Parents and/or legal guardians of children in the study must be fluent in English andcomplete all forms and questionnaires in English (for U.S. and Canadian research sitesonly)

Exclusion Criteria:

• Excluded from participating will be children with any of the following medicalconditions: cerebral palsy, Down's syndrome, traumatic brain injury, encephalitis,Lyme disease, cancer, any active infectious disease, endocrine disorder, other mentaldisorders such as psychotic disorders or other mood disorders including bipolardisorders, or any acute, chronic or unstable medical condition (such as a seizuredisorder, Crohn's disease, asthma, bronchitis, etc.) other than autism for which thechild has been receiving treatment, medication and/or therapy.

• Also excluded from the study are children who have undergone chelation therapy in thepast or are currently undergoing chelation therapy, and children who have displayedsignificant self-injurious behavior (children who have caused visible harm tothemselves).Children with a history of mild to moderate food or airborne allergies,sensitivities, or mild digestive problems are eligible to participate in the study.

• In order to participate in the study, children must not have received any previousNeuroModulation Technique treatment.